The distinct health risk analyses required for genotoxic carcinogens and promoting agents. by Weisburger, J H & Williams, G M
Environmental Health Perspectives
VoL 50, pp. 233-245, 1983
The Distinct Health Risk Analyses
Required for Genotoxic Carcinogens and
Promoting Agents
by John H. Weisburger* and Gary M. Wiliams*
Health risk analysis needs to apply newer developments in the understanding of the underlying
mechanisms of the carcinogenic process which has allowed for the classification of chemical carcin-
ogens into those that damage genetic material directly (genotoxic carcinogens) and those that oper-
ate by indirect or epigenetic mechanisms. We propose a systematic decision point approach for de-
tecting and evaluating substances for carcinogenic risk. This approach recognizes that genotoxic
and epigenetic agents operate by different mechanisms and distinguishes between these two cate-
gories of carcinogens primarily on the basis of results in a battery of short-term tests that includes
systems which reliably detect genotoxic carcinogens and others which may respond to epigenetic
agents. Genotoxic carcinogens at very low dosages may have practical, effective threshold no-effect
levels, but, nevertheless, because of their mechanism of action they are regarded as a qualitative
hazard. The action of epigenetic agents of the promoter class is highly dose-dependent and revers-
ible, and thus, a distinctively different health risk analysis is required for these agents to take ac-
count of their quantitatively lesser hazard.
Introduction
Substantial progress towards an understanding
of the risk factors for specific kinds of cancer and
the underlying mechanisms of carcinogenesis has
taken place in the last twenty years (1-3). This
knowledge of the nature of the carcinogenic process
has led to the recognition that chemicals which pro-
duce tumors in animals may do so by a variety of
modes of action.
Chemical carcinogens have been divided by Weis-
burger and Williams (4) into two broad categories
based upon their ability to damage genetic material,
or the lack thereof, and then further divided into a
total of eight subgroups (Table 1). A corollary of this
classification is that one type of health risk analysis
is appropriate for genotoxic carcinogens that dam-
age DNA, because of their specific mechanisms of
action, whereas agents that operate by indirect non-
genotoxic means require a different type of evalua-
tion (5, 6).
Genotoxic agents undergo a series of competing
reactions, ultimately reacting with DNA which ap-
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pears to be the critical event in carcinogenesis (Fig.
1). Once cell duplication with the so-generated ab-
normal DNA has occurred, the effect is basically ir-
reversible. In contrast, the action of agents oper-
ating by epigenetic mechanisms, which are as yet
unclear and require much more research, usually
necessitates their presence at high levels for a long
time and, indeed, is reversible up to a certain point.
Moreover, in many cases, their action is also tissue-
specific. For example, bile acids are powerful pro-
moters of colon cancer but act as inhibitors when
tested in the classic mouse skin system (7, 8). As
another example, there is sound evidence that sac-
charin belongs to the category of epigenetic agents
and acts as a promoter for cancer of the urinary
bladder (9-11). The many attempts to use standard
techniques of health risk analysis for saccharin have
yielded controversial results simply because such
techniques do not apply to this type of agent. In
fact, new procedures to define the mode of action of
nongenotoxic or epigenetic agents need to be devel-
oped for better risk evaluation.
This new understanding of the mechanisms of
carcinogenesis and the classification of chemical car-
cinogens has been made the basis of a rational, se-
quential system for evaluating the carcinogenic po-WEISBURGER AND WILLIAMS
Table 1. Classes of carcinogenic chemicals.
Type Mode of action Example
Genotoxic
1 Direct-acting or primary Electrophile, organic compound, Aziridine, bis(chloromethyl) ether
carcinogen genotoxic, interacts with DNA.
2 Procarcinogen or secondary Requires conversion through metabolic Vinyl chloride, benzo(a)pyrene, 2-naphthylamine,
carcinogen activation by host or in vitro to type 1. dimethylnitrosamine.
3 Inorganic carcinogen Not directly genotoxic, leads to changes in DNA Nickel, chromium.
by selective alteration in fidelity of DNA
replication.
Epigenetic
4 Solid-state carcinogen Exact mechanism unknown; usually affects only Polymer or metal foils, asbestos.
mesenchymal cells and tissues; physical form
vital.
5 Hormone Usually not genotoxic; mainly alters endocrine Estradiol, diethylstilbestrol.
system balance and differentiation; often acts
as promoter.
6 Immunosuppressor Usually not genotoxic; mainly stimulates "virally Azathioprine, antilymophocytic serum.
induced," transplanted, or metastatic
neoplasms.
7 Cocarcinogen Not genotoxic or carcinogenic, but enhances Phorbol esters, pyrene, catechol, ethanol,
effect of type 1 or type 2 agent when given at n-dodecane, SO2.
the same time. May modify conversion of
type 2 to type 1.
8 Promoter Not genotoxic or carcinogenic, but enhances Phorbol esters, phenol, anthralin, bile acids,
effect of type 1 and type 2 agent when given tryptophan metabolites, saccharin.
subsequently.
tential of chemicals (12). The key aim is to detect
substances posing potential health risks, as well as
to acquire knowledge as to which health risks are
associated with which kinds of cancer, via the sim-
plified, accelerated, more economical, and more reli-
able means afforded by the systematic decision
point approach. This system will be delineated as a
foundation for a discussion of elements required for
health risk analysis, itself an essential step in the
prevention of cancer.
The Decision Point Approach
The decision point approach involves five sequen-
tial steps, A-E, in evaluating the potential carcino-
genicity of a chemical (Table 2).
This approach was formulated to incorporate sev-
eral newer developments in carcinogenesis into the
evaluation of the toxic effects of a chemical. Of
prime importance was the concept that some chemi-
cals could produce an increase in the tumor inci-
dence in exposed animals, i.e., be carcinogenic, by
several distinct mechanisms, each having different
theoretical and practical implications. One of the
mechanisms proposed (3) involves the formation of
an electrophilic reactant which would react cova-
lently with cellular macromolecules. Work in sev-
eral laboratories (2-4, 13, 14) has strongly indicated
that DNA is in fact the critical cellular target. Other
chemicals, however, do not react covalently with
DNA but are nevertheless carcinogenic or onco-
genic in some animal bioassays. We, therefore, sug-
Table 2. Key steps in decision point approach
to delineate possible carcinogens or promoters.
Step
A Structure of chemical
B Battery of in vitro short-term tests
1. Bacterial mutagenesis
2. Mammalian cell mutagenesis
3. Mammalian cell DNA repair
4. Mammalian cell chromosome effects
5. Mammalian cell transformation
C Limited in vivo bioassays
1. Skin tumor induction in mice
2. Lung tumor induction in mice
3. Breast cancer induction in rats
4. Induction of altered foci in rodent liver
5. Tests for promoting effects
D Chronic bioassay
E Final evaluation
gested that chemical carcinogens could be divided
into two main categories based upon their capacity
to damage DNA.
Carcinogens that react covalently with DNA are
categorized as genotoxic, while those lacking this
property and probably acting by other mechanisms,
are designated as epigenetic. The genotoxic cate-
gory contains the classic organic carcinogens that
damage DNA either through direct chemical reac-
tivity or following metabolic activation by specific
enzyme systems (Fig. 1). In addition, in view of
some evidence for DNA damage or alteration, inor-
ganic carcinogens were tentatively placed in this
category (15).
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FIGURE 1. Diverse reactions of genotoxic carcinogens. A
procarcinogen undergoes biochemical host-mediated ac-
tivation to ultimate carcinogen, a reactive electrophile or
radical cation. Usually this activation step involves only a
small portion of a dose of procarcinogen, most of which is
detoxified by specific biochemical reactions, leading to
excretion. The potency of a carcinogen depends on the
ratio of activation/detoxification, itself a function of host
and environmental variables such as species, strain, sex,
age, diet, enzyme modifiers, and the like. The ultimate
carcinogen can also be detoxified or react with cellular
macromolecules not associated with carcinogenesis or
mutagenesis. Thus, only a minute fraction of the initial
dose of procarcinogen is usually productively involved in
the complex processes yielding neoplasm.
In contrast, the second category, epigenetic car-
cinogens, is composed of those agents that have not
been found to damage DNA but rather appear to
act through other indirect mechanisms. This cate-
gory contains several classes of agents such as plas-
tics, cytotoxic agents, hormones, immunosuppres-
sants, cocarcinogens and promoters, that operate by
distinctly nongenotoxic mechanisms.
The decision point approach distinguishes be-
tween these two categories of carcinogens by
testing in a battery of short-term tests that includes
systems which reliably detect genotoxic carcinogens
as well as others which may respond to epigenetic
agents. Implicit in this approach is that fact that all
forms of subchronic testing may fail to detect sub-
stances which can induce tumors in animals under
specific conditions upon chronic administration. The
battery of short-term tests may either eliminate the
need for further testing of the chemical or may
enable the verification of carcinogenic potential in
one of four limited in vivo bioassays for carcinoge-
nicity. The battery also adds essential information
for data evaluation and risk analysis when an' al-
ready completed chronic bioassay has yielded am-
biguous results.
The decision point approach, therefore is a sys-
tematic approach to the reliable evaluation of poten-
tial carcinogenicity that provides a framework in
which to minimize the necessary testing for evalu-
ating a chemical, without loss of the capacity for ac-
quiring essential information from which to draw
correct conclusions. At the same time, the system
through which data are collected provides an under-
standing of the mechanism of action of a chemical
that is essential to reliable risk extrapolation.
The decision point approach involves a system-
atic stepwise progression of tests through five
stages. At the end of each phase, a critical evalua-
tion of the information obtained and its significance
in relation to the testing objective is performed. A
decision is made as to whether the data available
are sufficient to reach a definitive conclusion or
whether a higher level of tests is required. Atten-
tion is paid to qualitative-yes or no- answers,
and to semiquantitative-high, medium or low-ef-
fects. The following outline has been described in
detail with full literature citation (5, 12).
Structure of Chemical
The evaluation of potential carcinogenicity begins
with a consideration of structure. Predictions as to
whether or not a given chemical might be carcino-
genic can be made with some success within certain
classes of chemicals, especially in the case of chemi-
cals of a type that includes known carcinogens. For
example, within the extensive series of azo dyes,
Miller and Miller, as well as Yoshida, Kinosita,
Druckrey, and Schmahl, have provided extensive
data on carcinogenicity as a function of structure.
Carcinogens of this type often have amino groups in
the para position of a benzene ring. Inclusion of rela-
tively polar substituents such as sulfonic acid abol-
ishes carcinogenicity. On the basis of this knowl-
edge alone, it is not likely that pure FD & C Red
No. 2 or FD & C Red No. 40, which bear such deac-
tivation substituents on both sides of the azo bond,
would be carcinogenic, and they have been found
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not mutagenic. On the other hand, more complex
tetrazo dyes that include a potentially carcinogenic
benzidine residue, available on biochemical reduc-
tion, are carcinogenic. Within the arylamine type of
chemicals, ortho-substituted (next to the vicinal
ring) polynuclear arylamines such as 1-naphthyl-
amine or 1-fluorenylamine are not carcinogenic,
whereas the 2-isomers are powerfully active in ro-
dents, and 2-naphthylamine is active also in humans.
This is because the 1-isomers do not undergo the re-
quired metabolic activation reaction ofN-hydroxyla-
tion to any significant extent, mainly because they
are rapidly detoxified by ring hydroxylation and
type II conjugation reactions.
Structure must always be consideed in relation to
species metabolic parameters. The guinea pig, for
example, in contrast to rodents or man, has only lim-
ited amounts of the necessary enzymes needed to
carry out N-hydroxylation and thus yields detoxi-
fied metabolites almost exclusively. Therefore, the
arylamines so far tested are not carcinogenic in this
species. Other examples of species selectivity based
upon metabolic capability are well documented.
More data are needed on the metabolic activation
and detoxification of important new heterocyclic
carcinogens or aliphatic carcinogens such as ethyl-
ene dibromide or 2-nitropropane. Data dealing with
structure and metabolism also yield a guide to the
selection among limited bioassays at stage C (see
below) and, as more information accrues, may con-
tribute to the choice of specific short-term tests at
stage B.
Battery of in Vitro Short-Term
Tests
Current views are that critical decisions can be
made only with a battery of such assays for toxico-
logical evaluations. The key element in the design of
an appropriate battery of tests is the formulation of
relevant criteria for selectivity of the best, most ef-
fective, and economical combination of tests. Also,
since testing schemes have become exceedingly
complex and expensive, it is important to reduce
the number of tests to an essential core without loss
of necessary information.
No decision should be made regarding the poten-
tial risk attached to chemical exposure by any route
until the entire data base is available from a battery
consisting of a group of selected tests. Implicit in
this philosophy is the concept that all available
short-term tests may yield false-positive or false-
negative results that require parallel data for
proper interpretation.
The selection of which tests will constitute a bat-
tery depends in part upon whether the goal is to de-
tect potential mutagens or carcinogens. Little is
known about the validity of mutagenicity batteries
because few chemicals have been shown to be germ
cell mutagens in experimental animals, and no
chemicals are known now that produce human
germinal mutations. Therefore, it would seem
prudent to design such batteries so as to identify
the broadest possible spectrum of genetic damage.
In contrast, carcinogenicity batteries can be verified
against in vivo data, albeit with an important quali-
fication. As indicated, evidence now supports the
concept that carcinogens operate by a variety of
mechanisms. Among these, DNA damage and its
biological consequences such as mutagenesis can be
readily detected in short-term tests. It is important
to realize that other oncogenic mechanisms of a non-
genetic nature are clearly not detectable in tests
with such genetic endpoints. Some tests such as ma-
lignant transformation and sister chromatid ex-
change, the results of which seem in some cases to
be produced by effects other than a direct attack on
DNA, may be capable of detecting non-DNA- dam-
aging agents. In addition, efforts are being made to
develop in vitro tests for identifying agents that op-
erate as tumor promoters (16-19).
As yet, however, none of the approaches for non-
genotoxic chemicals is sufficiently validated for
route inclusion in a battery. Therefore, in using bat-
teries to identify carcinogens, it must be recognized
that an entire class of chemicals containing such
agents as saccharin, hormones, certain organochlo-
rine compounds and pesticides and several pharma-
ceuticals may not be detected.
Several other principles should guide the con-
struction of a battery. Importantly, the tests should
be reliable and of clear biologic significance, and the
battery should seek to maximize the metabolic pa-
rameters provided by all tests. In particular, tests
with intact cell metabolism should be included to ex-
tend the metabolic competence obtained with the
commonly used exogenous enzyme preparations.
This may be of particular importance in view of the
differences in metabolism between subcellular and
cellular systems, in particular, the artifactual en-
hancement of activation over detoxification for cer-
tain classes of compounds that is known to be char-
acteristic of subcellular fractions and enzyme prepa-
rations.
Adhering to these concepts, a battery of short-
term tests was proposed by Weisburger and Wil-
liams (4,12,20) as part of the "decision point ap-
proach." This battery includes a microbial mutagen-
esis test, because, thus far, such tests have been the
most sensitive, effective, and readily performed
screening tests. In deciding what other tests to in-
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elude, it is important to consider what the candidate
test could contribute in terms of metabolic capabil-
ity and reliability and biologic significance of the
endpoint. The bacterial mutagenesis tests require a
mammalian enzyme preparation to metabolize
procarcinogens, and hence, any other test that is de-
pendent upon such an enzyme preparation does not
expand the battery's metabolic capability, which is
usually the key limiting component of a test series.
Thus, tests utilizing other indicators of DNA
change, but the same enzymic activation system,
may be similar in their capability simply because
their limitations are inherent in the metabolic prop-
erties. Such redundancies should be avoided by
using whole cell systems where possible.
Mutagenesis of mammalian cells is included in the
battery because it has a definitive endpoint, as has
bacterial mutagenesis, but involves effects on the
more highly organized eukaryotic genome. More-
over, differences in the mutagenic response be-
tween microbial and mammalian cells have been ob-
served.
DNA repair is a specific response to DNA dam-
age and, unlike other indicators such as DNA frag-
mentation and inhibition of DNA synthesis, cannot
be attributed to toxicity. Therefore, a DNA repair
test offers an endpoint of high specificity and bio-
logic significance. Moreover, the DNA repair test of
Williams using intact hepatocytes provides a whole
cell system in the battery.
A chromosomal test is included in the battery to
detect chemical effects at the highest level of ge-
netic organization. Sister chromatid exchange is
currently preferred because of its greater sensitiv-
ity compared to chromosome aberrations.
Cell transformation is included as an optional
part of the battery because this alteration is poten-
tially the most directly relevant to carcinogenesis.
Moreover, certain chemicals, without any other evi-
dence of genotoxicity, have yielded a positive re-
sponse in cell transformation, and thus this end-
point may be sensitive to epigenetic agents. How-
ever, reliable transformation assays are not widely
available, and more experience is needed to clarify
the significance and limitations ofthis endpoint.
Decision Point 1: Summary of Rapid in
Vitro Tests
In summary, these include tests for: (1) bacterial
mutagenesis, (2) mammalian mutagenicity tests, (3)
DNA damage, (4) chromosome effects, (5) cell trans-
formation. There are detailed reviews for the indi-
vidual tests of each type in the battery (21-23).
The steps recommended thus far, namely struc-
ture-activity relations and a sequence of rapid in
vitro tests, provide a basis for preliminary decision
making. A survey of literature data on the applica-
tion of the recommended tests has revealed a high
degree of sensitivity and specificity for this battery.
If clearcut evidence of genotoxicity in more than
one test has been obtained, the chemical is highly
suspect. Confirmation of carcinogenicity may then
be sought in the limited in vivo bioassays. This se-
quence avoids the necessity of resorting to the more
costly and time-consuming chronic bioassay, prob-
ably without loss of capability to reach reliable con-
clusions.
Evidence of genotoxicity in only one test must be
evaluated with caution. Several types of chemicals
such as intercalating agents are mutagenic to bac-
teria, but not reliably carcinogenic. Also, positive re-
sults have been obtained with synthetic phenolic
compounds or natural products with phenolic struc-
tures like flavones. In vivo, such compounds are
likely to be conjugated and excreted readily. Their
carcinogenicity, thus, would depend on in vivo split-
ting of such conjugates, which may occur more read-
ily in laboratory rodents than in man. Therefore,
positive evidence of bacterial mutagenesis only
must be evaluated in the light of the chemical struc-
ture and metabolism. Similar caution is required
when the sole evidence rests on tests for SCE or
cell transformation. Chemicals that are not obviously
genotoxic by other criteria have sometimes yielded
positive results in one or the other of such tests.
If all the preceding test systems yield no indica-
tion of genotoxicity, the priority for further testing
depends on two criteria: (1) the structure and known
physiological properties (e.g., hormone) of the mate-
rial, and (2) the potential human exposure. If sub-
stantial human exposure is likely, careful considera-
tion should be given to the necessity for additional
testing. The chemical structure and the properties
of the material provide direct obvious guidance on
the proper course of action. Organic chemicals with
structures suggesting possible sites of activation
may reveal their carcinogenicity in limited in vivo
bioassays. On the other hand, chemicals such as
solid-state materials, hormones, possibly some metal
ions, and organochlorine compounds that are nega-
tive in tests for genotoxicity operate by complex
and as yet poorly understood mechanisms, which in
many cases appear to involve tumor-enhancing ef-
fects. Thus, it is not certain that the limited in vivo
bioassays would yield any positive results with such
materials. Therefore, either specific promotional as-
says or the standard chronic bioassay are necessary
at this time to detect any potential activity with
these agents in relation to realistic human exposure
conditions. It is indeed urgent to develop reliable
means to detect such materials readily without re-
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quiring the large investment associated with a
chronic bioassay, especially if large numbers of peo-
ple have potential exposure to more than trace
amounts.
The testing of metal ions in rapid bioassay tests
may take advantage of the concept proposed by
Loeb (15) that such ions affect the fidelity of en-
zymes concerned with DNA synthesis. Obviously,
the nature of the metal ions, of which there are only
a limited number, would provide the necessary in-
sight as to the need for testing such a material fur-
ther and as to what kind of assay would most likely
reveal adverse effects.
Compounds with hormonelike properties other
than the strict androgen and estrogen types do
exist. Such chemicals are potential cancer risks
mainly because they interfere with the normal
physiological endocrine balance (24). More research
on ways and means to quickly test for such proper-
ties is required. It is known for example, that cer-
tain drugs lead to release of prolactin or other hor-
mones from the pituitary gland. Chronic intake of
such drugs causing a permanently higher serum
and tissue peptide hormone level might, in turn,
alter the relative ratio of other hormones. At this
time, any material with such properties needs to un-
dergo a chronic bioassay with carefully and appro-
priately selected doses to evaluate whether endo-
crine-sensitive tissues would be at higher risk. The
interpretation of data needs to take into account the
normal diurnal, monthly and even seasonal cycles of
the endocrine system and whether the test would
have led to interference in this balanced, rhythmic
system. It is essential to consider dosage and in-
clude in any bioassay a number of dose levels, in-
cluding any prevailing environmental or proposed
use levels.
The potential of polychlorinated cyclic hydrocar-
bons to act as promoters in the production of liver
tumors has been discussed in detail (25). As yet, the
structural requirements for promoting activity are
poorly understood, outside the class of phorbol
esters, and these promoting agents can be identified
only in initiation-promotion protocols in limited in
vivo bioassays or in chronic bioassay. New in vitro
systems for the detection of promoters (18,19,25)
may be promising also to delineate the effects of
such chemicals.
The implications of the absence of convincing
data for genotoxicity, but a positive response in
chronic bioassays, are discussed under the final
evaluation.
Limited in Vivo Bioassays
This stage of evaluation employs tests that will
provide further evidence of potential hazard of
chemicals positive for genotoxicity in the battery of
in vitro tests without the necessity of undertaking
an extensive chronic bioassay.
Thus, the in vivo tests recommended are those
that will provide definitive evidence of carcinogenic-
ity, including cocarcinogenicity and promotion, in a
relatively short period (i.e., 30 weeks or less). Unlike
the in vitro tests, these are not applied as a battery,
but rather used selectively according to the infor-
mation available on the chemical. A positive re-
sponse is a significant finding, especially for agents
that are genotoxic by the criteria defined above. On
the other hand, a negative finding in the limited in
vivo bioassays does not signify safety.
Skin Tumor Induction in Mice
The carcinogenicity of certain chemicals and
crude products can be noted readily upon continu-
ous application to the skin of mice, producing papil-
lomas or carcinomas, or upon subcutaneous injec-
tion, yielding sarcomas. Also, activity as initiating
agents can be rapidly determined by the concurrent
or sequential application of a promoter, such as one
of the phorbol esters. Tars from coal, petroleum, or
tobaccos are active in such systems, as are the pure
polycyclic aromatic hydrocarbons and congeners
contained in such products.
Mouse skin responds positively because it ap-
pears to have the necessary enzymes to yield the
active intermediates resulting in initiation, espe-
cially in the presence of cocarcinogens or promoters
in the crude products. On the other hand, such mix-
tures rarely yield visceral tumors such as those in
the liver, mainly because the liver can detoxify
these chemicals quickly. However, lung and lym-
phoid tumors in sensitive mouse strains can be sec-
ondary tumor sites.
Mouse skin is useful, primarily, therefore, for
chemicals such as polycyclic hydrocarbons, and also
direct-acting chemical carcinogens such as sulfur or
nitrogen mustard, bis(chloromethyl) ether, propio-
lactone, and alkylnitrosoureas.
Pulmonary Tumor Induction in Mice
Andervont and Shimkin pioneered with the
model involving the development of lung tumors in
specific sensitive strains of mice, especially the
A/Heston strain and related strains like A/J (1,12). A
singular advantage of this assay system is that, in
addition to an endpoint measuring the percent of
animals with tumor compared to controls, the multi-
plicity of tumors is an additional parameter express-
ing the "strength" of any carcinogenic action. Most
chemicals that are active in this system are also car-
cinogenic in other longer, chronic animal tests. Sig-
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nificant results are obtained in as short a time as
30-35 weeks, and sometimes faster.
Breast Cancer Induction in Female Sprague-
Dawley Rats
Shay discovered, and Huggins extended, the
finding that polycyclic hydrocarbons rapidly in-
duced cancer in the mammary gland of young
female random-bred Wistar rats and, to a greater
degree, in Sprague-Dawley rats (1,4). With powerful
carcinogens, especially select polycyclic hydrocar-
bons, arylamines, or nitrosoureas, a positive result
is obtained in less than nine months. The multi-
plicity of mammary tumors provides an additional
quantitative criterion. As with lung tumors in mice,
a positive response in this system has usually been
confirmed in other animal bioassay models. A nega-
tive response, however, does not prove lack of po-
tential carcinogenicity.
Altered Foci Induction in Rodent Liver
In the first version of the decision point approach,
production of rodent liver tumors was proposed for
limited in vivo bioassay. This concept is still valid,
but in recent years research in a number of labora-
tories has established that during liver carcinogene-
sis several distinct hepatocellular lesions precede
and are related to the development of carcinomas.
The earliest of these, the altered focus, when suffi-
ciently developed can be demonstrated in routine
histologic tissue sections. However, altered foci are
abnormal in a number of properties that permit
their reliable and objective identification at early
stages by more sensitive techniques. Altered foci in
rat liver display abnormalities in the enzymes y-
glutamyl transpeptidase (GGT), glucose-6- phospha-
tase, and adenosine triphosphatase which have been
used for their histochemical detection. Another
important marker for foci that permits histochemi-
cal identification is their resistance to iron accumu-
lation. This latter property is more sensitive than
the enzyme abnormalities and also, unlike the en-
zyme abnormalities, characterizes hamster and
mouse liver lesions. Thus, the induction of altered
foci in rodent liver can be used as a limited bioas-
say.
With known carcinogens, foci have been detected
as early as with three weeks of carcinogen expo-
sure, and in high numbers by 12 to 16 weeks expo-
sure. Therefore, the recommended approach is that
of 12 weeks exposure to the test chemical with in-
jection of subcutaneous iron during the last two
weeks to produce the iron load that delineates the
foci resistant to iron accumulation. The multiplicity
of the foci can be used for quantitative, or at least
semiquantitative estimation of relative potency,
when tests have been conducted under controlled
identical conditions. A positive control serves as a
standard reference point. Few carcinogens-have yet
been submitted to this technique, but based upon
current knowledge of the pathogenesis of liver can-
cer, this is anticipated to be a highly reliable test for
liver carcinogens. Since the liver is the target for so
many carcinogens because of its metabolic capabil-
ity (24), this test should possess substantial sensitiv-
ity.
Tests for Promoting Effects
In the absence of genotoxicity, it is possible to
test for one type of epigenetic effect in limited in
vivo bioassays, namely for promoting activity. For
example, mouse skin initiated with small doses of
genotoxic carcinogens such as benzo(a)pyrene or
7,12-dimethylbenz(a)anthracene responds readily to
certain tumor promoters. A material exhibiting en-
docrine properties likewise may show an effect in
modifying breast cancer induction in animals given
limited amounts of methylnitrosourea as an initi-
ating dose. Similarly, promoters of urinary bladder
cancer may be discovered by pretreatment with
limited amounts of a carcinogen specific for the
bladder (10,11,26). Similar systems can be developed
for virtually all organs, although one of potential
general utility is the liver system (27).
Decision Point 2: Summary of Limited in
Vivo Bioassays
The presence of two positive results in a battery
of rapid in vitro bioassay tests reliably indicating
genotoxicity, and also, a definite positive result in
the limited in vivo bioassays would make a sub-
stance highly suspect as a potential carcinogenic
risk to humans. This is true especially if these re-
sults were obtained with moderate dosages; more
so, if there was evidence of a good dose response,
particularly as regards the multiplicity of the lung
or mammary gland tumors.
Proven activity in more than one of the limited in
vivo bioassays may be considered unequivocal,
qualitative evidence of carcinogenicity. A wide
variety of structural types of chemicals are active in
one or more of these systems.
Chronic Bioassay
In the decision point approach, chronic bioassay is
used to confirm questionable results in the more
limited testing, or as a last resort measure to test
compounds negative in the preceding stages of test-
ing but where extensive human exposure is likely,
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or to acquire data on possible carcinogenicity
through epigenetic mechanisms. In this last situa-
tion, multispecies and dose response data are most
important if the data are to be applied to risk as-
sessment. Likewise, in this instance, if such an
agent is suspected of affecting a specific organ,
much time and expense can be saved by a short
course with a genotoxic carcinogen for that organ,
preceding the test of the epigenetic agent.
Chronic bioassays, especially at three to five dose
levels, are extraordinarily expensive. For this rea-
son, and in view of the fact that mice are more
likely to exhibit positive responses with agents
operating through epigenetic mechanisms, it may
be preferable to initiate such studies on dose re-
sponse only in mice. However, in the rare case
where both mice and rats are used, it will still be
important to utilize sufficient numbers of animals
and dose levels to enable the delineation of a dose-
response effect. In this instance, it will be important
to have the dose levels sufficiently spaced. One rec-
ommendation might be to determine the maximally
tolerated dose and to use that plus lower doses such
as 1/3, 1/9, 1/27, and 1/81, thus essentially covering
two log units. With compounds where a human ex-
posure level can be estimated, it may be useful to
include that level, and possibly three times that
level, as part of such a study. The conduct of chronic
bioassay has been described in a number of review
articles (1,4).
An important point is the estimation of the maxi-
mally tolerated dose in a subacute or prolonged
study. With relatively toxic compounds, the maxi-
mally tolerated dose will readily be found in sub-
chronic studies. With compounds that are not highly
toxic, arbitrary dose levels should be selected which
are consonant with the expected human exposure.
Thus, where humans are likely to have a relatively
low exposure rate, an arbitrary top dose of 0.5 or
1% in the diet or equivalent amounts through other
routes of intake would be sufficient. Where humans
might consume relatively large amounts, a propor-
tionately higher arbitrary top dose should be se-
lected.
In multidose tests, consideration should be given
to utilizing larger numbers of animals at the lower
dose levels so as to have better statistically valid
comparisons between the controls and the lower-
dose experimental groups where a lower response
would be expected to ensue.
Decision Point 3: Final Evaluation
If the decision point approach has led to a chronic
bioassay, then fairly definitive data on carcinogenic-
ity would be obtained. However, the results of the
in vitro short-term tests must be considered in the
evaluation of possible mechanisms for action and
risk extrapolation to humans. Convincing positive
results in the in vitro tests, coupled with docu-
mented in vivo carcinogenicity, permit classification
of the chemical as a genotoxic carcinogen.
Genotoxic carcinogens share a number of proper-
ties, including: the ability under some circumstances
to be effective as a single, large dose; cumulative ef-
fects; and synergism, or at least additive effects
with other genotoxic carcinogens. Genotoxic carcin-
ogens, therefore, represent clear qualitative hazards
to humans, and the level of exposure permitted
must be rigorously evaluated and controlled. Along
those lines, no distinction should be made between
naturally occurring and synthetic carcinogens. In
fact, there is growing evidence that the majority of
human cancers stem from exposure to the former
type of agents (28-30).
If, on the other hand, no convincing evidence for
genotoxicity is obtained, then the possibility exists
that the chemical is an epigenetic carcinogen. The
strength of this conclusion depends upon the rele-
vance of the in vitro tests. For example, the finding
that certain stable organochlorine pesticides do not
display genotoxic effects in liver cell systems, which
are identical to the in vivo target cell for these car-
cinogens, strongly supports the interpretation that
these carcinogens may act by epigenetic mecha-
nisms. The nature of these mechanisms is poorly un-
derstood at present, is probably quite different for
different classes of carcinogens, and may involve
chronic tissue injury, immunosuppressive effects,
hormonal imbalances, blocks in differentiation, pro-
motion of pre-existing altered cells, or processes not
yet known. A large number of carcinogens are now
known or suspected to exert their oncogenic effects
through promoting activity and therefore, the lim-
ited in vivo bioassay and in vitro systems for pro-
moters are of increasing importance. Most types of
epigenetic carcinogens share the characteristic of
being active only at high, sustained doses, and up to
a certain point, their effects may be reversible.
Thus, this type of carcinogen may represent only
quantitative hazards to humans, and safe levels of
exposure may be established by carrying out
proper toxicologic dose-response studies.
Quantitative Aspects and Health
Risk Analysis
The preceding stepwise decision point approach
leads to a qualitative "yes or no" answer to the
question of whether a given substance or a mixture,
as it might occur naturally or as a result of indus-
trial operations, constitutes a potential cancer risk.
The sequence of steps furthermore provides an indi-
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cation of possible mechanisms of action as regards
the important question of whether the substance
has genotoxic properties or whether it participates
in the overall complex sequence of steps involved in
cancer causation through nongenotoxic, epigenetic
actions. It is apparent from the modern conceptual
development presented in this review that a distinc-
tion between substances that are genotoxic and
those that are not is of key importance.
However, with each class, genotoxic carcinogens
and epigenetic agents, distinctions can and should
be made in relation to quantitative aspects. With re-
spect to genotoxic carcinogens, animal experiments
performed under similar conditions reveal that di-
etary intake of 100 ppb of aflatoxin B1 leads to the
high incidence of hepatocellular carcinoma in rats in
less than a year-and indeed this chemical can in-
duce liver cancer at levels as low as 1 ppb-while,
in contrast, safrole at dietary levels of 5000 ppm
yields liver cancer after a longer latent period. It is
obvious that the health risk analysis for two such
chemicals requires a different perspective in which
exposure to aflatoxin B, would be viewed as a
greater risk than safrole.
With agents that operate via nongenotoxic epige-
netic mechanisms, current concepts show that the
properties of such agents are quite different from
those that operate by genotoxic mechanisms. First
of all, their action appears to be reversible, so that
intermittent exposure of animals or humans does
not appear to constitute a risk if the intervals be-
tween exposures are sufficiently long for reversal of
effects. Indeed, if the action mimicks that of normal
diurnal or otherwise periodic cycling, as is true for
hormones, it may actually stabilize the physiological
system at specific dose levels. For example, low
doses of hormone, as in some current formulations
of oral contraceptives taken to mimic the rhythmi-
city of the normal menstrual cycle, may serve to
regularise the physiological hormonal pattern, thus,
approximating the optimal endocrine pattern. Thus,
physiologic doses given within a physiologic rhythm
are not likely to present abnormal risks. On the
other hand, higher dosages or continuing exposures
via long-lasting implants or injections most likely
would be a risk since endocrine balances would be
upset.
While classic promoters for mouse skin such as
phorbol esters (the active ingredients of croton oil)
have been studied for many years, it is unfortunate
that there are few quantitative data on the effect of
other epigenetic agents potentially involved in the
carcinogenic process. Thus, there have not been
many carefully conducted dose-response studies or
investigations dealing with the functioning of such
agents. As noted previously, this is a gap that needs
to be filled. Of great relevance and practical impor-
tance, are studies on the precise mechanism of ac-
tion for each kind of promoter as regards the organ-
otropism and the molecular events associated with
each kind of agent, whether they be hormones with
effects on the endocrine system, bile acids as they
affect the intestinal tract, or pesticides, drugs, artifi-
cial sweeteners or even the essential amino acid L-
tryptophan, as they might affect certain other
organs such as the liver or the urinary bladder.
Health Risk Analysis for Genotoxic
Carcinogens
There have been relatively few dose-response
studies with diverse genotoxic carcinogens. The
classic study of Bryan and Shimkin (31) has been uti-
lized by mathematical statisticians to>formulate the
theoretical shape of dose-response curves, especially
in extrapolations to low level effects. The experi-
mental design involved the subcutaneous injection
of three polycyclic aromatic hydrocarbons in mice
with the evaluation based on the detection of sar-
coma at the point of injection. With all three hydro-
carbons, the dose-response curve assumes an S-
shaped pattern typically seen in virtually all phar-
macological dose-response studies. In pharmacology,
it is possible with such curves to readily determine
a no-effect level. Indeed, the actual data in the re-
port by Bryan and Shimkin show that with the
three carcinogens there were several doses at the
low end which yielded no increase in tumors. None-
theless, because of the possible errors involved and
the relatively small number of animals used, mathe-
matical theory suggests that the overall response
might involve a one-hit linear model with no thresh-
old (32,33). Over the last 30 years, this experiment
has been interpreted in a number of different ways,
and it is the formulation of Cornfield (34) that seems
to approximate the actual experimental values best.
Health risk analysis, in our opinion, needs to take
into account the possible mechanisms of action of
carcinogens, especially procarcinogens, that require
metabolic activation and undergo detoxification not
only at the level of the procarcinogen itself but also
of the reactive electrophile, the ultimate carcinogen.
Indeed, the latter can undergo reaction with non-
specific cellular nucleophiles. Even DNA itself or
the chromosomal apparatus as a whole may not uni-
formly react at significant points with regard to
cancer induction. Thus, from the point of view of the
long sequence, starting with administration of a
procarcinogen leading to the specific cancer-
inducing molecular interaction, there are many non-
productive side reactions which leads us to suggest
that at very low dosages even with genotoxic
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agents there may indeed be practical, effective
threshold no-effect levels.
A number of more recent experiments, involving
more readily absorbed and excreted carcinogens, in
contrast to the polycyclic hydrocarbons used by
Bryan and Shimkin, that remain at the site of appli-
cation for a long time, point even more to the possi-
bility that there might be no-effect levels.
In the large-scale study conducted by the Na-
tional Center for Toxicological Research (NCTR) in-
volving dosages ranging from 150 ppm to 30 ppm of
N-2-fluorenylacetamide (or 2-acetylaminofluorene),
fed to mice, two organs were affected: the urinary
bladder and the liver (35). With tumors in the uri-
nary bladder, a definite no-effect level was found.
However, for liver tumors, especially for the groups
of animals that remained alive through 33 months, a
straight-line response was calculated from 150 to 30
ppm. It was further suggested that this response
corresponded to a linear model going through zero.
The experimental design aimed for a 1% response,
and for that reason large numbers of animals were
used at levels of 30, 40 and 45 ppm; as might be ex-
pected, the response of this complex biological sys-
tem was unable to discriminate among such closely
spaced doses. An intriguing question is what the re-
sponse might have been if the spacing of doses at
the lower end were greater and went, for example,
to 3 or even 1 ppm. We believe such levels would
have shown no appreciable effect even in large
samples. Such exposure levels to this chemical
would have been readily measurable chemically (36)
and correspond to human exposures which have
been the subject of concern.
Recently, a large-scale, dose-response experiment
was conducted in Great Britain with dimethylnitros-
amine and diethylnitrosamine (37). Dimethylnitrosa-
mine produced liver tumors, whereas diethylnitros-
amine produced cancer in the liver and in the esoph-
agus. It was found that the process leading to can-
cer in the esophagus demonstrated a threshold or
no-effect level. In a preliminary mathematical evalu-
ation of the response as regards liver carcinogene-
sis, the interpretation being made by pooling data
for both chemicals, both sexes, and all liver lesions,
there was evidence of a linear response even
through the lowest level used, 33 ppb. However, ex-
amination of the actual individual results by chemi-
cal, by sex, and by lesions, rather than from the
pooled data, would seem to indicate that the occur-
rence of tumors or lesions in the liver is random and
found in controls or treated groups in the three low-
est dose levels, namely 33, 66 and 132 ppb. The low-
est effective level, as revealed by inspection of the
actual data, would be 264 ppb and possibly even 528
ppb. Thus, the interpretation of this experiment re-
quires further expert review and discussion in re-
lation to health risk analysis. Regardless, the point
is that even with genotoxic carcinogens in a large-
scale, well-conducted experiment there is practical
and presumptive evidence, even though no mathe-
matical evidence, for a no-effect level.
The experimental evidence for no-effect levels for
genotoxic carcinogens, of course, can be challenged
by the contention that the data obtained are a func-
tion of the group size. Thus, even with relatively
large-scale experiments such as those described
above, the question has been raised whether the ap-
parent practical no-effect level would disappear if
the number of animals were to be increased, for ex-
ample, tenfold or a hundredfold. Such tests obvi-
ously are impractical. Nonetheless, decisions need
to be made in health risk analysis based on practical
rather than theoretical considerations. For example,
the United States Food and Drug Administration
(FDA) has ruled that a food crop such as corn or
peanuts that contains less than 20 ppb of aflatoxin
B1 can be marketed. This mycotoxin is a powerful
carcinogen, and under laboratory conditions 20 ppb
is an effective carcinogenic dose, albeit the custom-
ary dietary level for high yield, short latent period
tumor induction is 100-500 ppb (38). This naturally
occurring toxin has induced liver cancer not only in
the customary laboratory rodents but also in nonhu-
man primates. Thus it seems likely that this agent
would cause cancer in humans at that site. In tropi-
cal areas such as parts of Africa, China, and certain
other parts of Asia, where the dietary level of afla-
toxin is approximately 5-10 ppm or 200-500 times
higher than the action level in the Western world,
hepatocellular carcinoma is at present a major hu-
man neoplasm. On the other hand, in the United
States and other Western countries where people
have no doubt consumed foods contaminated with
this powerful carcinogen (discovered only in 1960
and controlled a few years later), primary liver can-
cer is a relatively rare disease. This not only justi-
fies the action of the EDA in establishing an action
level for aflatoxin B1, but it also suggests that there
are practical no-effect levels or at least no-effect sit-
uations with regard to even powerful carcinogens
such as aflatoxin B.
The conclusion is that, while more research and
better tools to delineate low-dose actions of geno-
toxic carcinogens are needed, it is also essential to
minimize human exposure to agents known to be
genotoxic. This is further imperative because of pos-
sible additive effects and the potential of situations
leading to tumor enhancement. Nonetheless, there
are now rigorous tests to establish whether or not a
given substance is genotoxic. Furthermore, it is pos-
sible to evaluate in semiquantitative terms the rela-
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tive strength of the expression of this genotoxic ef-
fect under in vivo conditions. At that point, rational
decisions can be made as to the kind of data needed
to evaluate rigorously the risk of the presence of
such agents in the human environment. Such con-
siderations need to be applied as much to naturally
occurring substances-some of which unquestion-
ably account for the current incidence of human
cancer-as to synthetic chemicals.
Health Risk Analysis for Tumor
Promoters
Health risk analysis dealing for tumor promoters
recognizes the fact that these agents operate under
mechanisms quite distinct from those applicable to
genotoxic agents. Their action is reversible and pre-
sumably highly dose-dependent. Unfortunately,
there have not been many studies on dose-response
with such agents. Where they were tested, it was
usually in the context of a carcinogen bioassay with
limited dose levels and dose ranges. Under these
conditions, it was apparent, however, that activity
was seen mainly at very high dose levels with a
sharp drop-off occurring as doses were lowered
even relatively slightly. Such findings were made
when testing, for example, saccharin and some
chlorinated hydrocarbons in the mouse liver tumor
system. It will be important to further delineate
such effects of dose on response in specifically de-
signed experiments with a genotoxic initiator, and
the promoter or epigenetic agent given at a number
of dose levels including one or two in the range of
practical exposure. In the instance of colon cancer,
where bile acids and bile acid concentrations appear
to be the relevant measures of promoting stimuli,
reduction of the concentration of total bile acids to
about one-third either by lowering the intake of di-
etary fat or by increasing the amount of dietary
fiber which increases stool bulk, converts a high
risk situation to one of lowered risk (7).
As we have noted, the concept of promotion in
chemical carcinogenesis is almost 50 years old. How-
ever, the focus of many of the early workers was on
the mechanism of action of croton oil and of phorbol
esters. The possibility of receptors for such com-
pounds being present in certain cells has been pos-
tulated, so that this kind of promoter may operate
by specific mechanisms not necessarily pertaining
to other agents such as saccharin or certain of the
chlorinated hydrocarbons such as DDT. In the case
of saccharin, a beginning has been made to deline-
ate a dose-response curve. In a model study, Cohen
et al. (10) demonstrated that saccharin, given after a
short course of FANFT, can act as a promoter when
given at 5% (50,000 ppm) in the diet. By utilizing a
different urinary bladder carcinogen, dibutylnitrosa-
mine, a dose-response curve was delineated (26). It
was found that for male and female rats, levels
lower than 10,000 ppm at 1% in the diet had no
effect. Likewise, despite a sizable national and inter-
national effort, epidemiological studies have failed
to demonstrate any effect of saccharin use in
humans, especially when corrected for confounding
factors such as cigarette smoking (39). In considera-
tion of the concepts developed in this paper, it will
be necessary to develop novel epidemiological strat-
egems in order to study the effect of agents in the
human environment that operate through pro-
moting rather than genotoxic mechanisms.
Along these lines it seems likely at this juncture
that a number of hepatocarcinogens, such as tri-
chlorethylene, tetrachlorethane, perchlorethylene
and above all DDT, are not genotoxic carcinogens
Table 3. Effect of DES or estradiol on mammary tumor induction in MT virus + or MTV- mice in 52 weeks.a
Mammary
Marked
Agent No. of ovarian Hyperplastic Adeno-
(ppb) mice atrophy alv. nodules carcinomas
C3H/HeJ (MTV + ) mice
0 47 20 0 4
10DES 32 31 3 0
lOODES 38 53 5 8
500 DES 48 100 14 7
100 E2 35 15 0 0
1000 E2 36 29 3 6
5000 E2 48 91 9 8
C3HeB/FeJ (MTV-) mice
0 18 11 0 0
10DES 39 0 0 0
100DES 18 33 0 0
500 DES 37 90 0 0
a From Highman et al. (43).
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but can act as promoters. There is virtually no reli-
able information as to dose response with these
chlorinated hydrocarbons studied as promoters. The
exception is a single study by Peraino et al. (40) of
liver tumor promotion by phenobarbital. In accor-
dance with the view that promoters would exhibit a
steep dose-response curve with a definite threshold,
there is no evidence at this time that these chemi-
cals have had any effect in enhancing human tumor
formation even though some people were exposed
in the course of their occupation to a number of
such chemicals such as perchlorethylene or DDT.
There have been a number of detailed epidemiologi-
cal studies of workmen involved in the manufacture
of DDT and of applicators of DDT who most likely
were exposed to higher levels than the general pop-
ulation; no evidence of excess cancers was noted
(41,42).
Hormones, especially estrogen, have been classi-
fied as promoters as well. A recent study by High-
man et al. (43) shows that, in mice bearing the mam-
mary tumor virus which acts as the genotoxic event
to yield cancers, DES or equi-estrogenic amounts of
the naturally occurring estradiol had a dose-related
effect in mammary carcinogenesis (Table 3). Of
great importance in the light of the concepts dis-
cussed, is the fact that in mice free of MTV, and
thus presumably with a normal genetic structure,
DES at any level did not produce mammary carcino-
genesis. This study illustrates the point that pro-
moters are not carcinogenic by themselves but re-
quire a specific antecedent gene change mediated
by an appropriate genotoxic reactant which can be
chemical, viral, or physical.
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